UCB Acquires Neurona to Advance Epilepsy Cell Therapy
BRUSSELS, Belgium, April 17, 2026 UCB, a global biopharmaceutical leader, has announced a definitive agreement to acquire Neurona Therapeutics...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BRUSSELS, Belgium, April 17, 2026 UCB, a global biopharmaceutical leader, has announced a definitive agreement to acquire Neurona Therapeutics...
